Celecoxib Reduces Prostaglandin E2 in Breast Cancer Risk Women
Author Information
Author(s): Edward R Sauter, Wenyi Qin, Lisa Schlatter, John E Hewett, John T Flynn
Primary Institution: University of Missouri
Hypothesis
Does a short course of celecoxib decrease PGE2 levels in women at increased breast cancer risk and those with established breast cancer?
Conclusion
Celecoxib significantly decreased PGE2 levels in nipple aspirate fluid of postmenopausal high risk women and in both nipple aspirate fluid and plasma of women with newly diagnosed breast cancer.
Supporting Evidence
- Celecoxib significantly decreased PGE2 levels in nipple aspirate fluid of postmenopausal high risk women.
- PGE2 levels decreased in both nipple aspirate fluid and plasma of women with newly diagnosed breast cancer.
- The study involved 39 subjects, with a majority being Caucasian and a median age of 53.
Takeaway
Celecoxib, a medication, can lower certain harmful substances in the fluid from women's breasts, which might help in preventing or treating breast cancer.
Methodology
Women at increased breast cancer risk and those with newly diagnosed breast cancer took celecoxib for two weeks, with samples collected before, after treatment, and after washout.
Potential Biases
Potential bias due to the small sample size and lack of a placebo control.
Limitations
The study's observations are preliminary and require larger studies for confirmation.
Participant Demographics
Majority were Caucasian, with a median age of 53 for high risk and 59 for cancer subjects; fewer than half were premenopausal.
Statistical Information
P-Value
p = 0.02 for postmenopausal high risk women; p = 0.02 and p = 0.03 for women with breast cancer.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website